Product Information
SIROLIMUS 0.5 MG TABLET is a generic product labeled by Ascend Laboratories, LLC, priced at $0.8415 per EA under NDC 67877074601. Its NADAC has been published 278 times since Jun 9, 2021.
FDA first approved this application on Mar 12, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/1
Manufacturer
Ascend Laboratories, LLCNDC
67877074601
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SIROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA214753FDA Approved
3/12/2021
TE Code
AB
On Market Since
3/13/2021
Pharmacological Classes
Price Statistics
The NADAC for SIROLIMUS 0.5 MG TABLET has been published 278 times since Jun 9, 2021, and over the history we have for it it has declined 85.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8415 per EA |
|---|---|
| All-time high | $5.9175 (Jun 16, 2021) |
| All-time low | $0.8415 (Sep 23, 2026) |
| 52-week high | $1.8025 |
| 52-week low | $0.8415 |
| Median price | $2.6674 |
| Average price | $3.0650 |
| Largest weekly change | -50.5% (Sep 20, 2023) |
| Weeks tracked | 278 |
| Tracking since | Jun 9, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Sirolimus market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ascend Laboratories, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sirolimus market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SIROLIMUS 0.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SIROLIMUS 0.5 MG TABLET, manufactured by Ascend Laboratories, LLC, is $0.8415 per EA (NDC 67877074601), effective Sep 30, 2026.
How has the price of SIROLIMUS 0.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for SIROLIMUS 0.5 MG TABLET has declined 85.8%. It has been tracked across 278 weekly CMS publications since Jun 9, 2021.
What are the highest and lowest recorded NADAC prices for SIROLIMUS 0.5 MG TABLET?
Since Jun 9, 2021, the NADAC for SIROLIMUS 0.5 MG TABLET has ranged from a low of $0.8415 (Sep 23, 2026) to a high of $5.9175 (Jun 16, 2021), with a median of $2.6674 per EA.
Are there cheaper alternatives to SIROLIMUS 0.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of SIROLIMUS 0.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SIROLIMUS 0.5 MG TABLET?
SIROLIMUS 0.5 MG TABLET (NDC 67877074601) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.